Marco Meglio

Of respondents who qualified for preventive treatment who were not currently using preventive medication, the majority (86.1%) had also never previously used preventive medication.

The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.

Bruce Leuchter, MD, a neuropsychiatrist and chief executive officer at Neurvati Neurosciences, provided insight on a recently published study showing that neurological diseases present the biggest global health threat.

ION582, delivered intrathecally into the cerebral spinal fluid with a lumbar puncture, resulted in significant improvements in cognition, fine and gross motor skills, and expressive communication.

In addition to demonstrating safety and tolerability, treatment with LM11A-31 resulted in significant differences in Aß40 and Aß42, although the ratio of Aß42 and Aß40 was not affected.

APN-1607 is undergoing a global phase 3 trial to evaluate its efficacy as an early diagnostic biomarker for progressive supranuclear palsy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.

Sean Pittock, MD, director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.

BIIB105, an antisense oligonucleotide, failed to demonstrate impact on outcomes of function, breathing, and strength, in addition to no impact on neurofilament light.

Voyager expects insights from the phase 1a study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.

Labeling updates underscore the importance of using compatible autoinjectors with specific glatiramer acetate injection products to prevent medication errors.

The study found that Black, Asian, and Hispanic individuals have 7- to 4-fold higher incidence of anti-NMDAR encephalitis, a rare epileptic condition, than White individuals.

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

In honor of Huntington Disease Awareness Day, held May 15, 2024, get caught up on some of the latest news in HD, with data updates and expert insights all in one place from the NeurologyLive® team.

Victor Sung, MD, PhD, director of the UAB Huntington’s Disease Clinic, provided perspective on some of the advances and areas of unmet on Huntington Disease Awareness Day.

The subcutaneous autoinjector, which facilitates 360 mg weekly maintenance dosing of lecanemab, takes less time to administer than the approved intravenous formulation and may lead to less hospital visits and nursing care.

Treatment with rozanolixizumab was safe among patients with CIDP, resulted in reduced immunoglobulin levels as expected, but did not have an impact on efficacy.

Using more than 4 million eligible pregnancies, results suggest no substantially increased risk of autism spectrum disorder after prenatal exposure to either topiramate or lamotrigine.

Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.

In patients with relapsing-remitting MS who achieved NEDA under highly effective DMT, sNfL concentrations were low and stable, suggesting a potential role for sNfL for long-term monitoring of inflammatory disease activity.

Bezisterim-treated patients showed age deceleration across various DNA methylation clocks, indicating potential anti-aging effects.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cluster headache.

Depression prior to PD diagnosis predicts increased dementia risk and mortality, emphasizing its significance in disease progression.

ABP-450, a botulinum toxin type A complex agent, failed to meet either primary or secondary end points in a cohort of 325 patients with chronic migraine.

Jacqueline A. French, MD, professor of neurology at NYU Grossman School of Medicine, provided comments on a recently published study explaining the issues with diagnosing epilepsy in emergency department settings.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Subgroup analyses support PrimeC’s potential in ALS treatment, aiming to inform upcoming trials for efficacy.

As the company gains more information about the patient death, dosing in the other phase 3 trial, CIFFREO, has been paused until further notice.

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.

STS101 demonstrated mild and predictable adverse events, suggesting potential efficacy at 5.2 mg dose for migraines.